Adipose tissue (AT) expansion is accompanied by the infiltration and accumulation of AT macrophages (ATMs), as well as a shift in ATM polarization. Several studies have implicated recruited M1 ATMs in the metabolic consequences of obesity; however, little is known regarding the role of alternatively activated resident M2 ATMs in AT homeostasis or how their function is altered in obesity. Herein, we report the discovery of a population of alternatively activated ATMs with elevated cellular iron content and an iron-recycling gene expression profile. These iron-rich ATMs are referred to as MFehi, and the remaining ATMs are referred to as MFelo. In lean mice, ~25% of the ATMs are MFehi; this percentage decreases in obesity owing to the recruitment of MFelo macrophages. Similar to MFelo cells, MFehi ATMs undergo an inflammatory shift in obesity. In vivo, obesity reduces the iron content of MFehi ATMs and the gene expression of iron importers as well as the iron exporter, ferroportin, suggesting an impaired ability to handle iron. In vitro, exposure of primary peritoneal macrophages to saturated fatty acids also alters iron metabolism gene expression. Finally, the impaired MFehi iron handling coincides with adipocyte iron overload in obese mice. In conclusion, in obesity, iron distribution is altered both at the cellular and tissue levels, with AT playing a predominant role in this change. An increased availability of fatty acids during obesity may contribute to the observed changes in MFehi ATM phenotype and their reduced capacity to handle iron.
Obesity is marked by the preferential accumulation of inflammatory M1 adipose tissue (AT) macrophages (ATMs), which play an important role in the development of AT inflammation and insulin resistance (IR) (1). The onset of AT dysfunction has important implications systemically, as AT inflammation and dysregulated lipolysis both promote ectopic lipid deposition and the accompanying metabolic consequences (2). Not surprisingly, a vast majority of the current literature is focused on mechanisms contributing to the recruitment and M1 polarization of infiltrating ATMs. Unfortunately, there remains a paucity of information regarding the physiological role of resident M2 polarized ATMs, as well as the manner by which resident ATM function is compromised in obesity. This represents an important gap in our current understanding of AT physiology, as defining the contribution of resident ATMs to AT homeostasis is a crucial step toward identifying the mechanisms underlying AT dysfunction in obesity.
Recently, the area of AT iron metabolism has received increasing attention. Adipogenesis, which is associated with the upregulation of various genes involved in iron metabolism (3), is induced by heme-iron through a REV-ERBα–mediated pathway (4,5). Interestingly, whereas iron overload induces adipocyte IR (6,7), strategies to reduce systemic iron concentrations (e.g., low-iron diet, chelation therapy, and phlebotomy) improve insulin sensitivity in obese animal models (8–10) and humans (6,11–13). The aforementioned evidence, combined with the fact that macrophages, as part of the reticuloendothelial system, play the predominant role in systemic iron recycling (14), raises the possibility that ATM iron handling contributes to AT homeostasis.
In the context of iron metabolism, macrophages are most commonly associated with their role in iron recycling for the purpose of providing an adequate supply of iron to support erythropoiesis, as well as to sequester iron as a bacteriostatic measure in response to acute infection (14). Recent data demonstrating that in vitro polarization dictates macrophage iron handling (15,16), combined with the increased M1 polarization observed in obesity, prompted us to explore the potential for ATMs to handle iron. Herein, we report the discovery of a population of alternatively activated resident ATMs that are natively ferromagnetic due to an elevated intracellular iron pool and display an iron-recycling gene expression profile. Additionally, we describe the influence of high-fat feeding on ATM iron handling and provide evidence for a systemic redistribution of tissue iron stores in obesity.
Research Design and Methods
Mice and Diets
Animal care and experimental procedures were performed in accordance with and approval by the Vanderbilt University Institutional Animal Care and Use Committee. Male C57BL/6J wild-type (WT) mice were purchased from The Jackson Laboratory (Bar Harbor, ME). At 8 weeks of age, mice were kept on a normal chow diet (NCD) or placed on low-fat (LFD) (10% kcal from fat, cat. no. D12450B; Research Diets) or high-fat (HFD) (60% kcal from fat, cat. no. D12492; Research Diets) diets for 16 weeks. The LFD and HFD both contain 10 g mineral mix (cat. no. S10026; Research Diets) per 4,000 kcal digestible energy, with each 10 g mineral mix providing 37 mg iron. Mice had free access to food and water throughout the study.
Mice were killed via cervical dislocation and perfused with PBS. Epididymal fat pads were removed, and the stromal vascular fraction (SVF) and adipocytes were isolated via collagenase digestion and differential centrifugation as previously described (17,18).
Magnetic Cell Sorting
Cells of the SVF were passed through an autoMACS magnetic-activated cell-sorting system (Miltenyi Biotec) to isolate natively ferromagnetic ATMs. After magnetic separation, nonferromagnetic and ferromagnetic fractions of the SVF were centrifuged at 500g for 10 min at 4°C and resuspended in fluorescence-activated cell sorter (FACS) buffer.
FACS Analysis and Sorting
The SVF was labeled with primary fluorophore-conjugated antibodies as previously described, and FACS analysis was performed on an LSRFortessa flow cytometer (BD Biosciences). Data were analyzed and figures generated using Cytobank (19). Isolation of MFehi and MFelo ATMs (F4/80hiCD11bhi) was performed using a FACSAria III cell sorter (BD Biosciences). The following antibodies, along with appropriate isotype controls, were used to characterize ATM populations: allophycocyanin-conjugated anti-mouse F4/80 (eBioscience), fluorescein isothiocyanate–conjugated anti-mouse CD11b (eBioscience), PE-conjugated anti-mouse CD206 (R&D Systems), phycoerythrin-conjugated anti-mouse MGL1/2 (R&D Systems), phycoerythrin-conjugated anti-mouse CD11c (eBioscience), phycoerythrin-conjugated anti-mouse CCR2 (R&D Systems), and CF594 (Biotium) conjugated anti-mouse CD163.
Male C57BL/6 mice were placed on a 60% HFD for 6 weeks, injected with 5 μmol/L PKH26 i.p., and maintained on HFD for an additional week. Approximately 90% of ATMs label with PKH26 (data not shown). At sacrifice, SVF cells were isolated and stained with allophycocyanin-conjugated anti-mouse F4/80 and DAPI. F4/80+PKH26+DAPI− and F4/80+PKH26−DAPI− macrophages were separated via FACS. Sorted cells were then further separated into MFelo and MFehi fractions using the Miltenyi AutoMacs sorter. Cell number in each fraction was determined by counting on a hemocytometer.
Primary Peritoneal Macrophage Isolation and Fatty Acid Treatments
Primary peritoneal macrophages (PPMs) were isolated from mice 3 days after injection with 2% thioglycollate. Cells were plated for 48 h followed by treatment with 500 μmol/L palmitic or oleic acid for 24 h as previously described (20). Cells were collected in TRIzol reagent for RNA isolation and real-time RT-PCR analysis.
RNA Isolation and Real-Time RT-PCR
RNA was isolated from liver using an RNeasy mini-kit (Qiagen) and from adipocytes and ATMs using TRIzol reagent (Invitrogen) according to the manufacturer’s instructions with minor modifications, including the use of 1-bromo-3-chloropropane (Sigma-Aldrich) and RNase-free glycogen (Roche Diagnostics). Additionally, RNA extracted from isolated adipocytes and ATMs was subjected to DNase treatment (DNA-free kit; Applied Biosystems). cDNA was synthesized using the iScript cDNA synthesis kit (BioRad), and real-time RT-PCR was performed on an iQ5 cycler (BioRad) using Taqman gene expression assays (Applied Biosystems [cat. nos. available upon request]). Gene expression for MFehi and MFelo cells was normalized to hypoxanthine guanine phosphoribosyl transferase or glyceraldehyde-3-phosphate dehydrogenase using the 2−∆∆Ct method (21). Expression for PPMs was normalized to cytochrome b.
Tissue Iron Visualization
Tissue iron distribution was visualized using the perfusion Perls’ Prussian blue staining method (22). Subsequent to perfusion with PBS supplemented with heparin (5 units/mL), mice were perfused with a Prussian blue staining solution containing 4% paraformaldehyde, 1% potassium ferrocyanide, and 1% HCl. One hour postperfusion, tissues were removed and incubated in staining solution for 12 h at 4°C prior to being paraffin embedded. Tissue sections were then cleared, hydrated, and counterstained with nuclear fast red.
Cellular and Tissue Iron Quantification
Ferromagnetic and nonferromagnetic ATMs were digested in ultra-pure HNO3. A double-focusing sector field high-resolution inductively coupled plasma mass spectrometry (ICP-MS) (ELEMENT II; Thermo Fisher Scientific, Bremen, Germany) equipped with ESI auto sampler was used for the quantitative analysis of ATM iron content in the isolated cells. The elemental measurement was performed on isotopes 25Mg, 42Ca, 55Mn, 56Fe, 59Co, 60Ni, 63Cu, and 66Zn at a mass resolution m/Δm 4,400 to separate molecular interferences. Elemental standards for external calibration were purchased from Fluka.
Splenic, hepatic, and adipocyte iron concentrations were measured with graphite furnace atomic absorption spectrometry (Varian AA240; Varian). Spleen and liver samples were homogenized in radioimmunoprecipitation assay buffer 1:10 w/v for protein determination using the bicinchoninic assay (Pierce Chemicals). An aliquot of the homogenate was then digested in ultra-pure HNO3 (1:3 v/v dilution) for 48–72 h at 60°C in a sand bath. Adipocyte pellets were homogenized in 100 μL radioimmunoprecipitation assay for bicinchoninic assay protein analysis, and aliquots were digested in 1:2 v/v ultra-pure HNO3. All digested samples were further diluted with a 2% nitric acid solution (1:20 to 1:100, as necessary) for analysis. Bovine liver (National Bureau of Standards, Standard Reference Material, United States Department of Commerce, Washington, DC) (184 µg Fe/g) was used as an internal standard for analysis.
Serum Iron Parameters
Total iron-binding capacity and serum iron, transferrin, and ferritin concentrations were quantified using an ACE Alera clinical chemistry system (Alfa Wasserman). Transferrin saturation was calculated as (serum iron/total iron-binding capacity) × 100%.
All data are reported and presented in figures as means ± SEM. Two-tailed unpaired t tests were used to compare means between two groups, and one-way ANOVA with the Tukey correction for multiple comparisons was used when comparing more than two groups. Statistical analyses were performed using GraphPad Prism (La Jolla, CA).
AT Contains a Population of Ferromagnetic Macrophages
A population of iron-containing ATMs distributed interstitially throughout the AT of lean, NCD-fed male WT mice was detected using the perfusion Perls' Prussian blue method (22) (Fig. 1A). This population was isolated from the SVF via magnetic column separation, yielding a ferromagnetic population and a nonferromagnetic population. Subsequent FACS using F4/80 and CD11b (Fig. 1B) demonstrated that 35% of nonferromagnetic cells were macrophages (Fig. 1C), compared with 90% of ferromagnetic cells. Unless otherwise indicated, subsequent experiments used a strategy of sequential magnetic/FACS to permit the direct comparison of viable ferromagnetic (MFehi) and nonferromagnetic (MFelo) ATMs. MFehi ATMs displayed a greater than twofold increase in cellular iron content compared with MFelo ATMs (Fig. 2A). For confirmation that the ferromagnetic properties of the MFehi cells were due to increased iron content as opposed to other ferromagnetic elements, ICP-MS was used to assess nickel and cobalt. In addition, copper, zinc, magnesium, calcium, and manganese were quantified (Supplementary Fig. 1). Only iron concentrations were significantly different between the MFehi and MFelo cells.
In addition to an elevated iron pool, MFehi ATMs exhibited a gene expression profile indicating a role in iron recycling (Fig. 2B). This included significantly greater expression of the genes involved in iron uptake (Cd163 and transferrin receptor-1 [Tfrc]), metabolism (heme oxygenase-1 [Hmox1]), storage (ferritin light and heavy chains [Ftl1 and Fth1, respectively]), and export (ceruloplasmin [Cp] and ferroportin-1 [Slc40a1]) in MFehi compared with MFelo cells. The upregulation of transferrin receptor and CD163, the hemoglobin-scavenger receptor, implicate uptake of iron by MFehi cells from various sources.
MFehi Are Alternatively Activated
In light of recent data suggesting that M2 polarization induces an iron recycling phenotype (15), we sought to determine the polarization of MFehi ATMs. While all ATMs from lean AT are expected to be M2-like (23), the expression of M2 markers, stabilin-1 (Stab1), macrophage galactose-type C-type lectin 1 (MGL1 [Clec10a]), and IL-10 (Il10) were significantly increased in MFehi compared with MFelo ATMs. In contrast, the M1 markers, CD11c (Itgax), CCR7 (Ccr7), and Il-1β (Il1b) were significantly reduced in MFehi cells (Fig. 2C). Flow cytometry also revealed that a significantly greater proportion of MFehi ATMs are CD163 and MGL1/2 positive, whereas a significantly reduced proportion of MFehi ATMs express the M1 markers, CD11c and CCR2 (Fig. 3).
Obesity Induces a Shift in MFehi Polarization Toward an Inflammatory M1 Phenotype
Next, mice were placed on an LFD or HFD for 16 weeks to determine the impact of obesity on the polarization and iron-handling phenotype of MFehi ATMs. As anticipated, HFD feeding increased the absolute number of ATMs (Fig. 4A), as well as the number of ATMs relative to AT mass (Fig. 4B). This increase was driven by a dramatic accumulation of MFelo ATMs, whereas the relative number of MFehi ATMs did not change after HFD. The marked accumulation of MFelo ATMs resulted in a significant decrease in the number of MFehi ATMs as a percent of total ATMs from 27% in lean controls to 14% in obese mice (Fig. 4C). Perls’ Prussian blue staining of AT revealed that MFehi ATMs are predominately, but not exclusively, located interstitially, with a small number associated with crown-like structures within obese AT (Supplementary Fig. 2). In agreement with the previously demonstrated inflammatory nature of recruited ATMs, MFelo ATMs isolated from obese mice display decreased gene expression of M2 markers and increased expression of M1 markers compared with MFelo ATMs from lean mice (Supplementary Fig. 3A). Despite retaining an alternatively activated gene expression profile relative to MFelo ATMs from obese mice (Supplementary Fig. 3B), HFD-fed compared with LFD-fed mice had decreased MFehi ATM gene expression of the M2 markers, Stab1 and Clec10a (Fig. 4D). The MFehi ATM population also exhibited an inflammatory shift, as HFD feeding increased Itgax, Ccr7, Tnfα, and Il1β expression by MFehi ATMs. As expected, flow cytometric analysis of MFelo cells demonstrated an increased M1-like profile in cells from HFD-fed mice (Supplementary Fig. 4). This shift was also noted in MFehi ATMs. Flow analysis indicated a decrease in MGL1/2 and CD206 expression in obese MFehi ATMs (Fig. 5A and B) and a significant increase in the proportion of MFehi ATMs expressing CD11c and CCR2 (Fig. 5C and D).
Obesity Impairs MFehi Iron Handling
The inflammatory shift observed by MFehi ATMs after HFD was associated with a significant reduction in iron content (Fig. 6A). This effect was restricted to MFehi ATMs, as high-fat feeding did not significantly influence MFelo ATM iron content. Interestingly, the inclusion of ATM iron data from NCD mice in our analysis revealed that MFehi ATMs from NCD and LFD mice possess similar iron content, as do MFelo ATMs from all three groups (Supplementary Fig. 5A). The impairment in MFehi ATM iron handling after HFD was apparent at the transcriptional level as well. High-fat feeding resulted in decreased MFehi ATM expression of genes involved in iron uptake, metabolism, storage, and export (Fig. 6B). Obesity produced similar relative changes in the expression of iron-handling genes by MFelo ATMs (Supplementary Fig. 3A).
For determination of a potential mechanism by which obesity alters macrophage iron handling, mouse PPMs were treated with 500 μmol/L palmitate or oleate (Fig. 6C). As expected, palmitate increased inflammatory genes such as Tnfα and Il6, while oleate increased M2 markers such as Clec10a and Cd163. Interestingly, expression of Ftl1 and Fth1 and the protein levels of hemoxygenase-1 were reduced in palmitate- but not oleate-treated PPMs. Expression of Slc40a1 was not altered by treatment with either fatty acid (data not shown). These studies indicate that saturated fatty acids released from IR adipocytes in obesity may contribute to the impaired macrophage iron handling observed during HFD feeding.
Macrophages Recruited During HFD Feeding Are MFelo
The identical number of MFehi ATMs relative to AT mass observed in LFD- and HFD-fed mice suggests that recruited macrophages do not take on a role in iron metabolism. To test this hypothesis, PKH26 labeling studies were performed. Mice were fed HFD for 6 weeks and then injected with PKH26 to label preexisting ATMs. One week after injection, the SVF was collected and sorted to isolate F4/80+PKH+ (pre-existing) and F4/80+PKH− (newly recruited) ATMs. Subsequently, magnetic sorting was used to quantify the proportion of MFehi and MFelo ATMs in each fraction (Fig. 7). Of the total cells counted, 60% were PKH+MFelo and 13% were PKH+MFehi, indicating that both MFelo and MFehi cells labeled with PKH were retained in the AT. Newly recruited PKH−MFelo cells made up 26% of the total ATMs. In contrast, only 0.2% of the PKH− cells were MFehi, indicating that recruited macrophages do not take on an MFehi phenotype.
Impaired MFehi Iron Handling Coincides With Adipocyte Iron Accumulation and Hepatic Iron Deficiency in Obesity
Despite the reduction in MFehi ATM iron content after HFD feeding, staining for tissue iron accumulation via perfusion Perls’ Prussian blue indicated that whole AT iron concentrations were increased in obesity (Fig. 8A). Interestingly, HFD feeding produced a fourfold increase in adipocyte iron concentration (Fig. 8B), as well as a gene expression profile consistent with iron accumulation (Fig. 8C). In addition to iron accumulation, adipocytes isolated from obese AT displayed an inflammatory shift in gene expression, including decreased Adipoq expression, upregulation of Il6, and a trend for increased Tnfα expression (Fig. 8D).
Importantly, our finding of adipocyte iron overload in obesity was not indicative of a global increase in tissue iron stores, as Perls’ Prussian blue staining and quantification of liver iron concentrations revealed a >50% reduction in obese mice compared with lean controls (Fig. 8E and F). Interestingly, this change in liver iron status did not elicit significant changes in the expression of genes associated with cellular iron handling (Fig. 8G); however, obesity reduced the expression of a specific cluster of genes important to the regulation of systemic iron homeostasis, including Trfr2 (transferrin receptor 2), Bmp6 (bone morphogenic protein 6), Tmprss6 (transmembrane protease, serine 6), and Hamp1 (hepcidin) (Fig. 8H). In contrast to the changes observed in hepatic and adipocyte iron concentrations, splenic iron concentrations were not significantly altered in obese mice, further pointing to a selective repartitioning of tissue iron stores in obesity (Supplementary Fig. 5B and C).
With regard to circulating iron parameters, serum iron concentrations were not influenced by obesity (Supplementary Table 1). In contrast, serum transferrin was significantly elevated following high-fat feeding, which is consistent with the hepatic iron deficiency observed in obese mice. Circulating ferritin concentrations were likewise increased in obese mice.
The past decade has witnessed a dramatic increase in our understanding and appreciation of the manner in which ATMs contribute to the metabolic consequences of obesity. Although the primary emphasis of the current literature lies with the contribution of ATMs to AT inflammation and IR, various studies have directly implicated ATMs in a number of homeostatic roles, including lipolysis (24), AT development (25), and remodeling (26). The current study demonstrates that resident ATMs are also involved in iron metabolism and lays the foundation for future investigations regarding a role for ATM iron handling in AT homeostasis, as well as the contribution of dysregulated ATM iron metabolism to AT function in obesity.
In light of the epidemiological evidence linking hyperferritinemia with obesity and related comorbidities (27), several studies have focused on the effects of altered iron metabolism on AT function (10,28) and the possibility that AT may play an active role in regulating systemic iron homeostasis (29,30). However, the potential contribution of ATMs to AT iron metabolism remains an unexplored area of investigation. The current study provides the first evidence that ATMs play a role in local AT iron metabolism and highlights the significant heterogeneity that exists with respect to an ATM iron-handling phenotype. Specifically, that obesity induces a selective decrease in MFehi ATM iron content and that infiltrating ATMs do not accumulate iron suggest that iron handling within AT is restricted to a discrete population of resident alternatively activated MFehi ATMs. Importantly, this paradigm is not without precedence, as splenic (i.e., red pulp, marginal zone, and metallophillic macrophages) and atherosclerotic plaque macrophage populations present similarly divergent roles regarding iron metabolism (31,32).
Recent studies describing the in vitro influence of polarization on macrophage iron handling suggest that M2 polarization induces an iron-recycling phenotype characterized by elevated Tfrc, Cd163, Hmox1, and Fpn expression and an increased capacity for iron uptake and release (15,16). In contrast, M1 polarization elicits an iron sequestration phenotype. Our in vivo data agree with this model insofar as MFehi ATMs present an iron-recycling gene expression profile (i.e., upregulation of iron importers and the exporter, ferroportin) and elevated expression of M2 markers. However, important differences exist with respect to MFehi ATM phenotype and the published in vitro model of M1/M2 macrophage polarization and iron metabolism (15,16). The in vitro model suggests that M2 polarized macrophages have a reduced capacity for iron storage and that M1 macrophages display an iron sequestration phenotype with an associated increase in ferritin heavy-chain expression. This stands in stark contrast to our finding of elevated iron content in alternatively activated MFehi ATMs. Likewise, based on the published model, one would predict that inflammation would lead to iron sequestration by M1 ATMs. On the contrary, our in vivo data suggest that obesity-associated inflammation does not increase recruited M1 ATM iron stores; rather, we observed a selective decrease in the iron content of MFehi ATMs coinciding with a shift toward an inflammatory phenotype. Furthermore, our studies demonstrate that treatment of macrophages with saturated fatty acids reduced genes and proteins associated with iron storage. Thus, it is possible that macrophage inflammation induced by fatty acids invokes different effects on iron metabolism compared with M1 polarization via traditional methods. Although the above discrepancies do not necessarily preclude the possibility that MFehi ATMs represent a subset of M2-polarized macrophages (i.e., M2a, -b, or -c) (33), the phenotype of MFehi ATMs more closely aligns with the recently characterized Mhem polarization state (31). Mhem macrophages are a discrete population of atheroprotective macrophages induced after intraplaque hemorrhage and the resultant heme exposure. Similar to MFehi ATMs, Mhem macrophages display elevated iron content and increased expression of Cd163, Hmox-1, and Il-10. Interestingly, the Mhem program is driven by heme-induced activating transcription factor-1 phosphorylation. Further research will be necessary to determine whether the observed MFehi phenotype is similarly regulated.
Results of the current study raise a number of important questions regarding the physiological relevance of ATM iron metabolism to AT function as well as the mechanism(s) underlying impaired MFehi ATM iron handling in obesity. Adequate control of iron availability appears crucial to AT homeostasis. Previous in vitro studies have demonstrated that heme-associated iron induces preadipocyte differentiation and is required to support adipogenesis (4,5). In contrast to its role in supporting adipogenesis, in vitro iron treatment induces lipolysis and IR in mature adipocytes (7,34). Furthermore, Gabrielsen et al. (6) recently used an elegant series of dietary and genetic manipulations to induce adipocyte iron overload and demonstrated that adipocyte iron regulates adiponectin expression and systemic glucose homeostasis. In agreement, we observed a significant decrease in adipocyte Adipoq gene expression after obesity-induced adipocyte iron accumulation. Interestingly, the occurrence of adipocyte iron overload in our study coincided with a reduction in MFehi ATM iron content and iron-recycling gene expression. In light of our findings and the available literature regarding AT iron metabolism, we propose a working model whereby resident MFehi ATMs fulfill the dual roles of providing an adequate supply of iron to support adipogenesis, analogous to macrophages acting as a source of iron for proliferating lymphocytes in the lymph nodes (35), and protecting adipocytes from oxidative stress by scavenging extracellular heme. Thus, impaired MFehi ATM iron handling in the setting of hyperinsulinemia, which induces adipocyte iron uptake (36,37), may play a role in the development of AT dysfunction in obesity. Future experiments are required to determine the role of resident ATM iron metabolism in AT homeostasis.
An intriguing aspect of the current study includes the observation of tissue iron repartitioning in obesity, which occurred in the absence of changes in serum iron concentrations. Specifically, hepatic iron concentrations were significantly decreased, whereas adipocyte iron concentrations were increased. Our finding of reduced hepatic iron stores and hepcidin expression is in line with previous studies in rodent models of obesity (38–40). Although our in vivo studies were not designed to address the underlying mechanism(s) responsible for changes in iron distribution, our data point to a potentially important interaction between iron and lipid metabolism. After 16 weeks of HFD, WT mice display visceral lipoatrophy accompanied by a dramatic increase in liver lipid accumulation (41). Likewise, high-fat feeding has been shown to induce ATM lipid accumulation (42). Interestingly, our data suggest that ectopic lipid accumulation in obesity is accompanied by a shift in tissue iron distribution, such that adipocytes display iron concentrations equivalent to the liver. Thus, sites crucial to the maintenance of systemic iron homeostasis (i.e., liver and macrophages) experience lipid accumulation coincident with a relative state of iron deficiency. Conversely, dysregulated lipolysis and atrophy of the AT are accompanied by adipocyte iron overload.
Increasing evidence points to important yet complex associations among adiposity, IR, and iron metabolism. The potential contribution of AT to systemic iron homeostasis has received increased attention recently; however, the role of ATMs in AT iron metabolism remains unexplored. The current study describes a novel population of alternatively activated MFehi ATMs that displays elevated cellular iron content along with an anti-inflammatory and iron-recycling gene expression profile. Importantly, the impairment of MFehi ATM iron handling is temporally associated with adipocyte iron overload and AT dysfunction in obesity. Additionally, our data provide the first evidence that diet-induced obesity leads to a repartitioning of tissue iron stores and argue for a coordinated regulation of lipid and iron metabolism. Collectively, our data lay the foundation for future investigations regarding the role of ATM iron handling in AT homeostasis and the mechanisms underlying the development of impaired iron metabolism in obesity.
Funding. This project was supported by a Discovery Grant in Innovative Diabetes Research from the Vanderbilt Diabetes Center (DK-20593) and National Institutes of Health (NIH) R21 DK-095456. The authors were supported by the following grants: NIH Ruth L. Kirschstein NRSA F32 DK-091040 (to J.S.O.), American Diabetes Association Mentor–based Postdoctoral Fellowship 7-10-MI-05 (to A.K.), American Heart Association Pre-doctoral Fellowship 12PRE11910047 (to E.K.A.-B.), NIH R21 DK-095456 (to C.D.W. and A.H.H.), and American Heart Association Established Investigator Award 12EIA8270000 (to A.H.H.). Flow cytometry was performed through Vanderbilt University Medical Center (VUMC) Digestive Disease Research Center supported by NIH DK-058404 Core Scholarship. Cellular iron measurements were performed by the VUMC Mass Spectrometry Research Core (supported by NIH Shared Instrumentation grant S10 RR-026742). Immunofluorescence imaging was conducted in part through the use of the VUMC Cell Imaging Shared Resource (supported by NIH grants CA-68485, DK-20593, DK-58404, HD-15052, DK-59637, and EY-08126). Serum iron parameter measurements were performed by the Vanderbilt Translational Pathology Shared Resource (supported by DK-059637).
Duality of Interest. S.K.M. is a minority shareholder of Cytoguide ApS (Aarhus, Denmark). The rat anti-mouse CD163 monoclonal antibody (E10B10) was a kind gift from Cytoguide ApS. No other potential conflicts of interest relevant to this article were reported.
Author Contributions. J.S.O. collected and analyzed data and wrote the manuscript. A.K., E.K.A.-B., C.D.W., S.C.F., K.M.E., Y.Z., A.E., and S.K.M. helped collect data and edit the manuscript. A.H.H. obtained funding, aided with data analysis, and edited the manuscript. A.H.H. is the guarantor of this work and, as such, had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.
This article contains Supplementary Data online at http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db13-0213/-/DC1.
- Received February 6, 2013.
- Accepted October 8, 2013.
- © 2014 by the American Diabetes Association.
Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. See http://creativecommons.org/licenses/by-nc-nd/3.0/ for details.